HeartBeam has announced a commercial partnership with ClearCardio, a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. The agreement represents HeartBeam's first commercial customer and includes plans for ClearCardio to make an investment in the company, indicating strategic alignment between the organizations.
The partnership will integrate HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention program for arrhythmia assessment. This integration enables patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system. The technology represents a significant advancement in remote cardiac monitoring, allowing physicians to identify cardiac health trends and acute conditions outside traditional medical facilities.
Structured as a Letter of Intent outlining subscription-based commercial terms and a collaborative deployment plan, the agreement supports HeartBeam's broader growth strategy. This includes expansion into concierge care and preventive cardiology networks, continued development of its 12-lead ECG patch monitor, and advancement of AI-driven cardiac care initiatives. The staged rollout approach ensures systematic implementation of the technology within ClearCardio's existing patient care framework.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software receiving clearance in December 2025. The company holds over 20 issued patents related to technology enablement, protecting its innovative approach to cardiac monitoring. The platform technology is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence to healthcare providers.
This partnership has significant implications for the cardiac care industry, particularly in the growing field of remote patient monitoring and preventive cardiology. By enabling clinical-grade ECG readings from home, the technology addresses accessibility challenges in cardiac care and supports early detection of arrhythmias. The collaboration between a medical technology company and a preventive cardiology practice represents a model for integrating innovative technologies into clinical workflows to improve patient outcomes.
The commercial agreement follows regulatory milestones for HeartBeam's technology and demonstrates market validation for its approach to cardiac monitoring. As preventive cardiology continues to gain importance in healthcare systems focused on reducing hospitalizations and improving population health, technologies that enable effective remote monitoring become increasingly valuable. The partnership positions both companies at the intersection of medical technology innovation and preventive healthcare delivery.
For more information about HeartBeam's regulatory filings and disclosures, visit https://ibn.fm/BEAT. Additional legal information regarding forward-looking statements and risk factors can be found at http://IBN.fm/Disclaimer. These resources provide context for understanding the regulatory environment and business considerations surrounding medical technology innovations in cardiac care.
